BioTime Issues Dual Listing On TASE

September 9, 2015 | The US company BioTime announced that it will dual list on the Tel Aviv Stock Exchange. The developer of cell-based therapies has a market cap of $268 million and two Israeli subsidiaries, Cell Cure Neurosciences and LifeMap Sciences. BioTime’s shared are expected to be included on all five of the TASE’s equity indexes. BioTime was founded in 1992 and is based out of Alameda, California.